Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
Back to Results

  • Non-Relapse Mortality After CAR T-Cell Therapy in Patients with Lymphoma

    Cancer Categories
    • Hematologic (Blood Cancers)
    Karmanos Trial ID
    • 2025-063
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionQuestions, please contact us
    • N/A
    Principal Investigator
    • Image of Dipenkumar Modi , M.D.
      Dipenkumar
      Modi, M.D.
      Oncology - Hematology, Oncology - Medical View Profile

    Objective:

    Primary Objectives:

    • To determine the cumulative incidence of non-relapse mortality (NRM) at 30 days, 100 days, and 1 year following CAR T-cell therapy in patients with lymphoma.

    Secondary Objectives:

    • To identify risk factors associated with NRM after CAR T-cell therapy.
    • To describe causes of death contributing to NRM (e.g., CRS, ICANS, infections, organ failure).
    • To compare clinical characteristics and CAR T-related toxicities between patients who experienced NRM and those who did not.
    • To assess the impact of NRM on overall survival (OS) and progression-free survival (PFS).
    Request an Appointment
    Refer a Patient
    NCI Dictionary of Cancer Terms
    KCI Clinical Trials App
    • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 1-800-527-6266